Site search
2901 results for '' found
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Pat
/
A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN126
A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment. (ACTRN126
/
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
PERsonalised Selection Of medication for Newly diagnosed Adult epiLepsy (ACTRN12623000209695)
/
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
Perampanel for the prevention of post-stroke epilepsy: a pilot phase II randomised controlled trial (ACTRN12618001984280)
/
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmon
A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmon
/
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myel
/
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
ORganoId GuIded N-of-1 (ORIGIN-1) trial (ACTRN12623001136695)
/
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (ISRCTN42400492)
/
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
A Phase 3, open-label, randomized study to compare the efficacy and safety of Odronextamab [REGN1979], an Anti-CD20 X Anti-CD3 bispecific antibody, versus investigators choice in previously untre
/